A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220568

Enrollment

240

Registered

2008-06-10

Start date

2008-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus.

Interventions

investigational material(s) Generic name etc : SYR-322 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : O

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Key Criteria for inclusion: - The subject has been taking a stable dosage regimen of pioglitazone for at least 16 weeks prior to the initiation of the treatment period (Week 0) - The subject has an HbA1c value of 6.5% or more and below 10.0% at 14 weeks after the initiation of the screening period (Week -2) Key Criteria for exclusion: - The subject has taken any antidiabetic medications except pioglitazone within the last 16 weeks prior to the initiation of the treatment period (Week 0) - The subject with a history or symptoms of heart failure

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HbA1c change at the completion of treatment from baseline	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026